PT738390E - Substitutos para alvos e paineis de referencia melhorados - Google Patents

Substitutos para alvos e paineis de referencia melhorados

Info

Publication number
PT738390E
PT738390E PT95906754T PT95906754T PT738390E PT 738390 E PT738390 E PT 738390E PT 95906754 T PT95906754 T PT 95906754T PT 95906754 T PT95906754 T PT 95906754T PT 738390 E PT738390 E PT 738390E
Authority
PT
Portugal
Prior art keywords
panels
reactivity
receptor
panel
members
Prior art date
Application number
PT95906754T
Other languages
English (en)
Inventor
Lawrence M Kauvar
Hugo O Villar
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/177,673 external-priority patent/US5587293A/en
Application filed by Telik Inc filed Critical Telik Inc
Publication of PT738390E publication Critical patent/PT738390E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Laminated Bodies (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PT95906754T 1994-01-06 1995-01-05 Substitutos para alvos e paineis de referencia melhorados PT738390E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/177,673 US5587293A (en) 1994-01-06 1994-01-06 Method to identify binding partners
US08/308,813 US5798275A (en) 1994-01-06 1994-09-19 Profiling reference panel enriched by non-IG proteins

Publications (1)

Publication Number Publication Date
PT738390E true PT738390E (pt) 2003-07-31

Family

ID=26873529

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95906754T PT738390E (pt) 1994-01-06 1995-01-05 Substitutos para alvos e paineis de referencia melhorados

Country Status (11)

Country Link
US (1) US5741653A (pt)
EP (1) EP0738390B1 (pt)
JP (1) JPH09507300A (pt)
AT (2) ATE359509T1 (pt)
AU (1) AU700497B2 (pt)
CA (1) CA2178096C (pt)
DE (2) DE69530179T2 (pt)
DK (2) DK1235072T3 (pt)
ES (2) ES2196056T3 (pt)
PT (1) PT738390E (pt)
WO (1) WO1995018969A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
AU5902098A (en) * 1997-01-03 1998-07-31 Terrapin Technologies, Inc. Method to classify gene products
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
NZ504483A (en) 1997-11-12 2002-11-26 Dimensional Pharm Inc High throughput method for functionally classifying proteins by contacting the protein with different molecules and determining the effect on the proteins stability
CA2314422A1 (en) * 1997-12-18 1999-06-24 Sepracor Inc. Methods for the simultaneous identification of novel biological targets and lead structures for drug development
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
JP2002522750A (ja) * 1998-08-05 2002-07-23 ユニバーシティ・オブ・ピッツバーグ シトクロムｐ４５０媒介反応における有機化合物の反応性のモデル化
US6625547B1 (en) 1998-08-05 2003-09-23 Washington State University Research Foundation Relative rates of cytochrome p450 metabolism
JP2002522779A (ja) * 1998-08-12 2002-07-23 ザイコス インク． 発現蛋白質タグのプロファイリングおよびカタログ化
US20040224338A1 (en) * 1998-08-12 2004-11-11 Zycos Inc., A Delaware Corporation Profiling and cataloging expressed protein tags
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
EP3712897A1 (en) * 2019-03-22 2020-09-23 Tata Consultancy Services Limited Automated prediction of biological response of chemical compounds based on chemical information

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300425A (en) * 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5338659A (en) * 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
US4963263A (en) * 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5217869A (en) * 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
ATE152244T1 (de) * 1987-10-13 1997-05-15 Terrapin Tech Inc Verfahren zur herstellung von imunodiagnose- mitteln
US5340474A (en) * 1988-03-24 1994-08-23 Terrapin Technologies, Inc. Panels of analyte-binding ligands
IE904705A1 (en) * 1989-12-29 1991-07-17 Univ Technologies Int Methods for modelling tertiary structures of biologically¹active ligands including agonists and antagonists thereto¹and novel synthetic antagonists based on angiotensin
EP0556327A1 (en) * 1990-11-09 1993-08-25 Verigen, Inc. Method for determining the sensitivity and/or specificity of an assay system for detecting antibodies

Also Published As

Publication number Publication date
DK1235072T3 (da) 2007-07-16
AU1522195A (en) 1995-08-01
JPH09507300A (ja) 1997-07-22
CA2178096A1 (en) 1995-07-13
ATE236401T1 (de) 2003-04-15
AU700497B2 (en) 1999-01-07
WO1995018969A1 (en) 1995-07-13
EP0738390B1 (en) 2003-04-02
ES2196056T3 (es) 2003-12-16
DE69530179D1 (de) 2003-05-08
ATE359509T1 (de) 2007-05-15
DE69530179T2 (de) 2004-04-08
DK0738390T3 (da) 2003-07-21
DE69535463D1 (de) 2007-05-24
CA2178096C (en) 2004-03-09
EP0738390A1 (en) 1996-10-23
ES2284743T3 (es) 2007-11-16
US5741653A (en) 1998-04-21
DE69535463T2 (de) 2008-01-03

Similar Documents

Publication Publication Date Title
PT738390E (pt) Substitutos para alvos e paineis de referencia melhorados
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
BR9508417A (pt) Acido nucléico isolado cdna isolado proteina isolada vetor de expressão processo para detectar câncer e pré-câncer de pulmão processo para selecionar especimes humanas para proteina hcaviii processo para testar amostra de célula humana anticorpo e composição terapêutica
PT914344E (pt) Ensaio e reagentes para a quantificacao de hbnp
BR9106217A (pt) Processo para a analise de uma amostra de gas,disposicao de analise,empregos disto e instalacao de teste com a citada disposicao
ATE461450T1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
BR9712298A (pt) Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão
ATE113962T1 (de) Von polypeptiden induzierte monoklonale antikörper gegen oncoproteine.
Righetti et al. The proteome: anno Domini 2002
Segura et al. Procedures for monitoring recombinant erythropoietin and analogues in doping control
DK1117685T3 (da) Behandling af inflammatorisk sygdom
ATE258310T1 (de) Testverfahren für collagenpeptid
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
DK26587A (da) Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette
DE69018968D1 (de) BLUTGERINNUNGSFAKTOR BETA XIIa MONOKLONALE ANTIKÖRPER UND IMMUNANALYSE.
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
PT98073A (pt) Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 beta por metodos recombinantes e de composicoes farmaceuticas que os contem
SE0003566D0 (sv) A method for the quantitative determination of one or more compounds
DK0789844T3 (da) Anvendelse af et BMP-proteinreceptor-kompleks til screening for aktive stoffer i knoglemetabolisme og celler, der er cotransficieret med en type II-BMP-receptor og en type I-BMP-receptor
Gooderham In situ peptide mapping of proteins following polyacrylamide gel electrophoresis
DK162726C (da) Fremgangsmaade til eliminering af falsk positive resultater ved bestemmelse af atl virus-antistof og reagens dertil
Dunn Quantitative amino acid analysis
ATE249047T1 (de) Verfahren zum spezifischen nachweis von glykosilierten proteinen
EA200000658A1 (ru) Способ и реагенты для количественной оценки реакций в твердой фазе с использованием ямр фтора
Yokohama et al. Proteome analysis of cashmere